We are proud to announce that VOXCAN and BIOASTER have joined forces to develop preclinical models for COVID-19.
By combining our technologies, our collaboration will help Pharma and Biotech companies accelerate the search for COVID-19 therapies and vaccines that are sorely needed.
Together, VOXCAN and BIOASTER commit to provide robust, modular and customizable SARS-CoV-2 in vitro and in vivo models, with longitudinal monitoring based on virological, immunological or histopathological read-outs, to evaluate new or repurposing drug candidates in a therapeutic or prophylactic manner.
#Infectious diseases, COVID-19, SARS-CoV-2, Virus, Antiviral, Vaccines, Preclinical studies
